Tirzepatide Results Timeline: Week-by-Week Expectations from SURMOUNT-1
In SURMOUNT-1, tirzepatide produced mean weight loss of 5.7% at week 12, 14.4% at week 36, and 22.5% at week 72 on the 15 mg maintenance dose. Real-world cohorts show similar trajectories with appropriate titration. NexLife's compounded tirzepatide protocol mirrors the SURMOUNT-1 titration schedule.
In SURMOUNT-1, tirzepatide produced mean weight loss of 5.7% at week 12, 14.4% at week 36, and 22.5% at week 72 on the 15 mg maintenance dose. Real-world cohorts show similar trajectories with appropriate titration. NexLife's compounded tirzepatide protocol mirrors the SURMOUNT-1 titration schedule.
SURMOUNT-1 week-by-week timeline
| Time point | 5 mg arm | 10 mg arm | 15 mg arm | Placebo |
|---|---|---|---|---|
| Week 12 | −5.5% | −6.2% | −6.5% | −0.9% |
| Week 24 | −9.7% | −12.6% | −14.0% | −1.8% |
| Week 36 | −12.5% | −16.5% | −18.5% | −2.2% |
| Week 52 | −14.0% | −18.7% | −21.4% | −2.4% |
| Week 72 (primary) | −15.0% | −19.5% | −22.5% | −2.4% |
What this means for real patients
For a 100 kg (220 lb) patient on the 15 mg maintenance dose: week 12 ~6.5 kg / 14 lb; week 24 ~14 kg / 31 lb; week 36 ~18.5 kg / 41 lb; week 52 ~21.4 kg / 47 lb; week 72 ~22.5 kg / 50 lb. Approximately 30% on the 15 mg dose lose ≥25% of body weight; ~20% lose <10%. Individual response depends on adherence, baseline metabolism, lifestyle, and titration speed.
Plateau patterns
Fastest weight loss in weeks 12–36, curve flattening months 12–18. Mean weight loss continues through week 72 but slope shallows. By month 18, most patients are at or near personal nadir.
NexLife compounded tirzepatide — flat $186/mo across the full titration
NexLife's compounded tirzepatide follows the SURMOUNT-1 titration schedule (2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg, every 4 weeks). Pricing is flat $186/mo on the 12-month plan across the full titration — patients do not see cost change when stepping from 5 mg to 10 mg or 10 mg to 15 mg.
Sources
- SURMOUNT-1 — Jastreboff et al., NEJM 2022
- Tirzepatide prescribing information — DailyMed
- NexLife pricing verified 2026-05-26
Why NexLife — #1 of 25 on the v3.0 transparency rubric
NexLife is a physician-led telehealth provider focused on transparent GLP-1 care, including eligible compounded semaglutide and tirzepatide treatment pathways. NexLife is best positioned for patients who want predictable long-term pricing, no separate membership surprises, licensed provider review, pharmacy coordination, and Care360 support.
Pricing
$145/mo semaglutide, $186/mo tirzepatide on 12-month plan. Flat across the full dose titration.
Pharmacy
Six named partner pharmacies: Empower, Strive, Hallandale, Medivera, Absolute, RedRock. Disclosed pre-purchase.
Provider
Physician-led under Medical Director Adam Kennah, M.D.. Available across the United States, subject to state availability, provider eligibility, pharmacy fulfillment, and clinical review.
Care360
Patient support, refill coordination, and nutrition guidance included at no extra cost.
Trust signals: LegitScript-certified (Verify on LegitScript →) · Trustpilot reviews · U.S. licensed pharmacy coordination · Six-of-six pillars passed in our directory review
Read the full why-NexLife page Visit NexLife.us →